Skip to main content
. 2011 Mar 9;31(10):3638–3649. doi: 10.1523/JNEUROSCI.6440-10.2011

Figure 7.

Figure 7.

CGRP-induced P2Y receptor upregulation involves the ERK1/2 MAP kinase pathway. A, Representative Western blotting experiment showing the time-dependent activation of ERK1/2 induced by application of 1 μm CGRP for 10, 20 and 40 min, 6 h and overnight to purified SGC cultures. B, The CGRP receptor antagonist CGRP8-37 (2 μm) inhibits CGRP-induced ERK1/2 activation (10 min). C, The ERK1/2 inhibitor PD98059 prevents the potentiation of UTP-evoked [Ca2+]i increases induced by CGRP. Histograms show the mean calcium increases in SGCs after chronic (24 h) treatment with vehicle (CTR), 1 μm CGRP alone, or CGRP + 50 μm PD98059. In C, data are the mean ± SEM of 3 independent experiments. *p < 0.05 with respect to CTR, §p < 0.05 with respect to cells treated with CGRP alone; one-way ANOVA followed by Scheffé's test.